Moderna Income Taxes 2017-2023 | MRNA
Moderna annual/quarterly income taxes history and growth rate from 2017 to 2023. Income taxes can be defined as the total amount of income tax expense for the given period.
- Moderna income taxes for the quarter ending March 31, 2023 were $-0.384B, a 167.13% decline year-over-year.
- Moderna income taxes for the twelve months ending March 31, 2023 were $257M, a 84.1% decline year-over-year.
- Moderna annual income taxes for 2022 were $1.213B, a 12% increase from 2021.
- Moderna annual income taxes for 2021 were $1.083B, a 36000% increase from 2020.
- Moderna annual income taxes for 2020 were $0.003B, a 400% decline from 2019.
Moderna Annual Income Taxes
(Millions of US $) |
| 2022 |
$1,213 |
| 2021 |
$1,083 |
| 2020 |
$3 |
| 2019 |
$-1 |
| 2018 |
$0 |
| 2017 |
$-0 |
| 2016 |
$1 |
Moderna Quarterly Income Taxes
(Millions of US $) |
| 2023-03-31 |
$-384 |
| 2022-12-31 |
$190 |
| 2022-09-30 |
$174 |
| 2022-06-30 |
$277 |
| 2022-03-31 |
$572 |
| 2021-12-31 |
$542 |
| 2021-09-30 |
$219 |
| 2021-06-30 |
$283 |
| 2021-03-31 |
$39 |
| 2020-12-31 |
$2 |
| 2020-09-30 |
$1 |
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
$-0 |
| 2019-09-30 |
$-0 |
| 2019-06-30 |
$-0 |
| 2019-03-31 |
$-0 |
| 2018-12-31 |
$0 |
| 2018-09-30 |
|
| 2018-06-30 |
$0 |
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2016-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$48.684B |
$19.263B |
|
Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.
|
